All GLG News Analyses Filed Under: Business of Medicine

R & D investment from pharmaceuticals has been the main source of research in the development of new treatment

The article is presenting an overview of pharmaceutical and biotechnology companies active participation to  develop drugs based on immune medicine for a growing list of ailments, and successful outcomes are reported from growing rate of sale. The value of Immune factor drugs worldwide has...

This article is presenting an overview of performance from immune drugs to treat patients afflicted with heretofore intractable conditions. The promising growth in sale is showing the good prospect of serving as a impetus for further development for immune drugs.  The success of immune drugs has...

1. Do doctors accept bribes? 2. Would a bribe affect a doctors usage of a product 3. Is there a need for a greater crack down on bribes?

The article is showing a promising medical intervention to treat intracellular protein changes due to disease and ageing, at least for human population after a positive outcome obtained from a research with 88 men exposed to respiratory syncytial virussyncytial virus.  RNAi Drug is believed...

1)  Baxter was producing 50% of the worlds heparin requirements, which provided short term anticoagulation for hemodialysis and various interventions for cardiovascular disease. 2)  The base product of heparin comes from porcine intestines. 3)  The base product of Baxter's heparin was...

1)  Amgen's and J&J's ESA products are going to continue to receive more black box warnings from the FDA. 2)  A federal Judge may force Amgen to accept a royalty from Roche, allowing their CERA ESA to come to market in the USA. 3)  Their is potential for more problems to arise,...

Misys Healthcare, a wholly owned subsidiary of Misys Plc of Great Britain, will be merged with a wholly owned subsidiary of Allscripts. Misys Plc will contribute $330 million in cash to Allscripts, for which it will receive shares representing a 54.5% ownership position in the combined  company.  ...

GSK has planned to change their pricing strategies to bolster sales of various products.

The most obvious (potential) benefit to Lilly of its collaboration agreement with Transition is that it will be adding one more potential class of diabetic therapies to its product line.  Lilly already has Humulin (longer-acting insulin), Humalog (a rapid acting insulin), Actos and exenatide (a...